BIT Capital GmbH Has $900,000 Holdings in Merus (NASDAQ:MRUS)

BIT Capital GmbH lifted its position in Merus (NASDAQ:MRUS - Free Report) by 167.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,402 shares of the biotechnology company's stock after purchasing an additional 13,402 shares during the quarter. BIT Capital GmbH's holdings in Merus were worth $900,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC raised its stake in shares of Merus by 10.4% in the 3rd quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company's stock valued at $343,421,000 after buying an additional 648,994 shares in the last quarter. Wellington Management Group LLP raised its position in Merus by 73.6% in the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company's stock worth $144,260,000 after purchasing an additional 1,224,573 shares in the last quarter. Franklin Resources Inc. lifted its stake in Merus by 7.1% during the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company's stock worth $117,722,000 after purchasing an additional 150,341 shares during the period. Holocene Advisors LP boosted its holdings in Merus by 4.1% during the third quarter. Holocene Advisors LP now owns 1,637,988 shares of the biotechnology company's stock valued at $81,834,000 after purchasing an additional 64,122 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its stake in shares of Merus by 83.0% in the 3rd quarter. Lord Abbett & CO. LLC now owns 723,988 shares of the biotechnology company's stock valued at $36,171,000 after purchasing an additional 328,316 shares during the period. 96.14% of the stock is owned by institutional investors.

Remove Ads

Merus Price Performance

Shares of MRUS stock traded down $4.08 on Monday, reaching $40.54. 765,789 shares of the stock were exchanged, compared to its average volume of 630,651. Merus has a one year low of $37.77 and a one year high of $61.61. The stock has a market cap of $2.80 billion, a PE ratio of -10.26 and a beta of 1.15. The stock has a 50 day moving average price of $43.98 and a 200 day moving average price of $46.03.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $9.14 million during the quarter, compared to analysts' expectations of $10.57 million. On average, research analysts expect that Merus will post -3.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MRUS has been the subject of several analyst reports. Guggenheim restated a "buy" rating and set a $109.00 target price on shares of Merus in a research report on Friday. Piper Sandler initiated coverage on shares of Merus in a research note on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. Citigroup increased their target price on shares of Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Wells Fargo & Company assumed coverage on shares of Merus in a report on Friday, February 7th. They set an "overweight" rating and a $91.00 price target for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Merus in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $85.31.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.